Segall Bryant & Hamill LLC raised its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 97.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 80,354 shares of the biopharmaceutical company's stock after buying an additional 39,721 shares during the period. Segall Bryant & Hamill LLC owned 0.07% of Catalyst Pharmaceuticals worth $1,677,000 as of its most recent filing with the SEC.
Other hedge funds have also recently modified their holdings of the company. Rhumbline Advisers increased its holdings in Catalyst Pharmaceuticals by 0.3% during the fourth quarter. Rhumbline Advisers now owns 312,320 shares of the biopharmaceutical company's stock worth $6,518,000 after buying an additional 952 shares during the last quarter. Handelsbanken Fonder AB increased its stake in shares of Catalyst Pharmaceuticals by 2.9% during the 4th quarter. Handelsbanken Fonder AB now owns 35,477 shares of the biopharmaceutical company's stock worth $740,000 after purchasing an additional 1,000 shares during the last quarter. Xponance Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 6.8% in the 4th quarter. Xponance Inc. now owns 18,763 shares of the biopharmaceutical company's stock worth $392,000 after purchasing an additional 1,189 shares during the period. Steward Partners Investment Advisory LLC purchased a new position in Catalyst Pharmaceuticals in the fourth quarter valued at approximately $27,000. Finally, Farther Finance Advisors LLC grew its holdings in Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock valued at $56,000 after purchasing an additional 1,495 shares during the period. Institutional investors own 79.22% of the company's stock.
Insider Transactions at Catalyst Pharmaceuticals
In other news, insider Brian Elsbernd sold 62,975 shares of the firm's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the sale, the insider now owns 188,564 shares in the company, valued at approximately $4,333,200.72. This trade represents a 25.04 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Gary Ingenito sold 44,904 shares of the company's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the transaction, the insider now owns 68,873 shares of the company's stock, valued at $1,521,404.57. This trade represents a 39.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.00% of the stock is owned by insiders.
Catalyst Pharmaceuticals Stock Performance
Catalyst Pharmaceuticals stock traded down $0.37 during midday trading on Tuesday, hitting $23.89. 609,163 shares of the company's stock were exchanged, compared to its average volume of 1,112,590. The company has a market cap of $2.90 billion, a P/E ratio of 20.23, a PEG ratio of 3.31 and a beta of 0.84. The stock has a 50-day moving average price of $22.69 and a two-hundred day moving average price of $21.86. Catalyst Pharmaceuticals, Inc. has a 52-week low of $14.47 and a 52-week high of $26.16.
Analyst Ratings Changes
A number of brokerages have recently commented on CPRX. Stephens reaffirmed an "overweight" rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, February 27th. HC Wainwright reaffirmed a "buy" rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Bank of America reiterated a "buy" rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. StockNews.com raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 28th. Finally, Robert W. Baird raised their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a report on Monday, March 3rd. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $32.29.
Check Out Our Latest Research Report on Catalyst Pharmaceuticals
About Catalyst Pharmaceuticals
(
Free Report)
Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
Read More
Before you consider Catalyst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Catalyst Pharmaceuticals wasn't on the list.
While Catalyst Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
